Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: GlobalData
Provider: Wright Reports
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

TG Therapeutics Inc's Ublituximab Receives Orphan Drug Designation For Treatment Of Nodal Marginal Zone Lymphoma And Extranodal Marginal Zone Lymphoma

Monday, 9 Sep 2013 07:30am EDT 

TG Therapeutics Inc announced that ublituximab (TG-1101), the Company's glycoengineered anti-CD20 monoclonal antibody has received two Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for the treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma (Mucosa-Associated Lymphatic Tissue, MALT), both rare subtypes of non-Hodgkin's lymphoma (NHL) for which there are limited effective treatments. 

Latest Developments for TG Therapeutics Inc

Company Quote

0.14 +2.73%
17 Apr 2014